Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2003;326:1124 (24 May), doi:10.1136/bmj.326.7399.1124
F Verdon, general practitioner1, B Burnand, senior lecturer2, C-L Fallab Stubi, pharmacist3, C Bonard, general practitioner1, M Graff, general practitioner1, A Michaud, general practitioner1, T Bischoff, general practitioner1, M de Vevey, general practitioner1, J-P Studer, general practitioner1, L Herzig, general practitioner1, C Chapuis, general practitioner1, J Tissot, general practitioner1, A Pécoud, professor3, B Favrat, consultant of internal medicine3
1 General Practice Unit, University of Lausanne, rue du Bugnon 44, 1011 Lausanne, Switzerland, 2 Health Care Evaluation Unit, Institute of Social and Preventive Medicine, University of Lausanne, 3 Medical Outpatient Clinic, University of Lausanne
Correspondence to: B Favrat bernard.favrat{at}hospvd.ch
Design Double blind randomised placebo controlled trial.
Setting Academic primary care centre and eight general practices in western Switzerland.
Participants 144 women aged 18 to 55, assigned to either oral ferrous sulphate (80 mg/day of elemental iron daily; n=75) or placebo (n=69) for four weeks.
Main outcome measures Level of fatigue, measured by a 10 point visual analogue scale.
Results 136 (94%) women completed the study. Most had a low serum
ferritin concentration;
20 µg/l in 69 (51%) women. Mean age,
haemoglobin concentration, serum ferritin concentration, level of fatigue,
depression, and anxiety were similar in both groups at baseline. Both groups
were also similar for compliance and dropout rates. The level of fatigue after
one month decreased by -1.82/6.37 points (29%) in the iron group compared with
-0.85/6.46 points (13%) in the placebo group (difference 0.95 points, 95%
confidence interval 0.32 to 1.62; P=0.004). Subgroups analysis showed that
only women with ferritin concentrations
50 µg/l improved with oral
supplementation.
Conclusion Non-anaemic women with unexplained fatigue may benefit from iron supplementation. The effect may be restricted to women with low or borderline serum ferritin concentrations.
Randomisation, main outcome, and adherence to treatment
Our study was a pragmatic randomised placebo controlled trial. Participants
received either 80 mg/day oral long acting ferrous sulphate (Tardyferon;
Robapharm, Boulogne) or placebo for four weeks. Iron and placebo were
identical in appearance and taste and for dose regimen. Randomisation took
place at an independent pharmacy, according to a pre-established list.
Patients, caregivers, and investigators were blinded to treatment assignment
until the end of the trial. Each drug package was coded with a unique number
according to the randomisation schedule and then posted to the relevant
practice. The codes were held by the pharmacist and remained unbroken until
the analyses were completed.
The main outcome was the level of fatigue perceived by patients, assessed
at baseline and after one month on a 10 point visual analogue scale, ranging
from 1 (no fatigue at all) to 10 (very severe fatigue). Also used was a
validated 24 item self administered questionnaire incorporating eight items
for each of three dimensions (fatigue, anxiety, and
depression).10
Levels of depression and anxiety were examined as additional outcomes. Each
item was scored on a visual analogue scale. A cumulative score was obtained
for each dimension by adding the eight item scores (range 0-40). The patients
were asked about any potential side effects and intercurrent physical,
psychological, and haemorrhagic events. Serum ferritin concentration and
adherence to treatment were measured and considered as intervening variables.
A complete blood count was obtained at baseline, and the serum ferritin
concentration was measured by chemoluminometric immunoassay. Clinicians could
order other tests to rule out any disorder to explain the fatigue. Serum
ferritin concentration was measured after one month in those patients whose
initial value was
20 µg/l.
Adherence to treatment was measured by an electronic device (MEMS; Aardex Europe, Switzerland), which recorded the date and time that the pill container was opened.11 Unused pills were also counted. Adherence was quantified by dividing the number of times the device was opened by the total number of days of observation. Patients were asked not to take over the counter vitamin or iron supplements.
Statistical analysis
An estimated sample size of 63 patients was needed to detect a one point
difference between the groups on the visual analogue scale. The calculation
included an estimated standard deviation of two points for a two tailed test
(
=0.05, power=0.80). We calculated changes in symptom levels and scores
over time for each patient by subtracting the results at follow up from those
at baseline. The principal analysis was performed according to an intention to
treat protocol. Tests performed were two sample t tests,
2 tests, and linear regression analyses. A per protocol
analysis was also conducted.
50 µg/l
in 115 (85%) patients and
20 µg/l in 69 (51%) patients.Scores for
anxiety and depression were low in both groups.
|
|
The mean decrease in the overall intensity of fatigue between zero and one
month was higher in the iron group than in the placebo group (-1.82 (SD 1.7)
-0.85 (2.1) points, difference 0.95 points 95% confidence interval 0.32
to 1.62, P=0.004; table 2). By
choosing a cut-off point of 50 µg/l, we found that there was no
quantitatively significant response greater than 50 µg/l (P=0.64). The iron
group showed the largest decrease in the cumulative score for fatigue (-7.5
(8.0)
-4.6 (7.5) points, difference 3.0 points, 0.3 to 5.6, P=0.03). The
difference for depression was not statistically different between the two
groups (-2.1 (6)
-1 (7) points, P=0.31), whereas a greater decrease in
anxiety was observed in the iron group (-1.7 (6)
1.3 (6), P=0.003).
|
After adjustment for age, initial levels of depression and anxiety, and serum ferritin concentration in a multiple linear regression analysis, iron supplementation was the most important variable to be associated with the decrease in the overall intensity of fatigue, an effect corresponding to -1 point on the visual analogue scale. Younger age was also associated with a larger decrease in the intensity of fatigue.
A multiple linear regression analysis in the iron group showed that age, initial levels of depression and anxiety, serum ferritin concentration, and haemoglobin concentration were not predictive of the mean decrease in the overall intensity of fatigue. The best predictor of response was the amount of pills consumed in the iron group, but this was not so in the placebo group.
Compliance and dropout rates were similar in both groups: 95% (12)
98%
(9), P=0.25) for compliance and4of75(5%)
4 of 69 (6%) for dropout rates
in the iron arm and placebo arm, respectively. After the intervention, serum
ferritin concentrations were highest in the iron group (21.0 (SD 9.2)
13.7 (6.9), P < 0.001). After exclusion of five patients, a per protocol
analysis was no different from the intention to treat analysis.
Women with fatigue often associate their symptoms with psychosocial stressors and not a possible emotional or biomedical cause.4 16 17 Conversely, medical investigators tend to associate fatigue with emotional causes and more rarely with biomedical causes.46 16 18 We found that iron deficiency may be an under-recognised cause of fatigue in women of childbearing age. Thus, identifying iron deficiency without anaemia as a potential cause of fatigue is important. It may avoid the inappropriate attribution of symptoms to putative emotional causes or life stressors and thereby reduce unnecessary use of healthcare resources. Instituting iron therapy early may also improve quality of life.8
We found a significant response only in the patients with a baseline serum
ferritin concentration
50 µg/l. This suggests that iron deficiency
could be present even with a "normal" concentration of serum
ferritin. Indeed, the lower limit for serum ferritin concentration is
controversial: iron stores in the bone marrow may serve as a better indicator
of iron
deficiency.19 One
study compared serum ferritin concentrations with iron stores in the bone
marrow and found that a serum ferritin concentration of 50 µg/l was
associated with a 50% chance of iron deficiency occurring in the bone
marrow.20 The lower
reference limits for serum ferritin and haemoglobin concentrations have been
considered too low for
women.21 The
authors of that study advocate the adoption of the same reference values for
both men and women that "would be expected to have fundamental and
positive implications for women's health and welfare." Our study
indirectly supports their conclusion by showing that women can benefit from
iron supplementation even if their red blood cell counts are considered
normal.
Iron deficiency even in the absence of anaemia is associated with decreased activity of iron dependent enzymes and therefore affects the metabolism of neurotransmitters.2223 In people with iron deficiency anaemia the related symptoms will disappear more quickly than the accompanying increase in haematological indices.24 This suggests that some cellular functions are affected by iron treatment independently of haemoglobin concentration. We did not, however, measure haemoglobin concentration after exposure to iron and therefore did not assess whether people who had low but normal haemoglobin concentrations had an increase in haemoglobin concentration that could be associated with a decrease in fatigue.
Limitations of study
Our study has several limitations. Firstly, blinding for group assignment
is an important issue, especially with iron, because of the side effects. It
was not possible to correct for the change in stool colour by adding bismuth
to the placebo because bismuth is an active substance. To minimise the side
effects we used a low dose iron sulphate taken with breakfast. Participants in
both groups were also told that their drug could colour stools. We did not ask
the participants to guess their group assignment. In a recent placebo
controlled trial no significant differences in guesses about treatment were
found between iron and placebo groups despite the elemental iron dose used
being three times that of our
study.14 We found
no difference in compliance between the two groups suggesting that the
patients did not recognise that they had been assigned to placebo. Secondly,
we did not have a procedure to control recruitment of all consecutive eligible
patients, because this would have been difficult to apply in a busy clinical
practice. Thirdly, ferritin concentration was the only measure of iron status
in the study because it is considered the best non-invasive indicator of iron
storage.20 Finally,
our primary outcome focused on fatigue, a patient centred subjective
measure.
|
Contributors: FV, BB, CLF, and BF participated in the conception and design of the study, analysis and interpretation of data, drafting and revising the manuscript, and inclusion of patients for BF and FV. CB, MG, AM, TB, MdeV, J-PS, LH, CC, JT, and AP participated in the conception and design of the study, inclusion of patients, and drafting and revising the manuscript. BF will act as guarantor for the paper.
Funding: This study was sponsored by Robapharm. The sponsor was not involved in the analysis of the results nor in writing or correcting the manuscript.
Competing interests: FV and BF received financial support from Robapharm for producing a preliminary report of the study.
Ethical approval: The study was approved by the ethical review committee for clinical research of the Department of Internal Medicine, University of Lausanne.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
Read all Rapid Responses